论文部分内容阅读
研究开发了一种具有新的作用机制的化合物,针对该化合物的早期研究显示可以改善2型糖尿病患者的血糖控制。TAK-875在不同剂量水平降低HbA1c的速率优于格列美脲(glimepiride),Prabhakar
Research has developed a compound with a new mechanism of action, and early studies of the compound have shown to improve glycemic control in patients with type 2 diabetes. The rate at which TAK-875 reduced HbA1c at different dose levels was superior to glimepiride, Prabhakar